{"filings":[{"id":1138680,"accession_number":"0001104659-26-075730","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2026-06-18T20:14:48+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Ironwood shareholders approve 10M share increase to equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment increasing shares available under 2019 Equity Incentive Plan from 16M to 26M.","All eight director nominees elected with over 97% of votes cast in favor.","Non-binding advisory vote on executive compensation passed with ~95% of votes cast in favor.","Ratification of KPMG as independent auditor for 2026 approved with ~97% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1056490,"accession_number":"0001104659-26-074023","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2026-06-15T20:05:31+00:00","items":["8.01"],"status":"ready","headline":"Ironwood repays $200M 1.50% convertible notes due 2026 at maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $200M aggregate principal of 1.50% convertible senior notes due 2026 at scheduled maturity.","Funded repayment with available cash on hand; no conversions exercised by holders.","Capped call transactions previously entered into in connection with notes terminated upon expiry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":581803,"accession_number":"0001104659-26-065140","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K/A","filed_at":"2026-05-21T20:05:34+00:00","items":["5.02"],"status":"ready","headline":"Ironwood appoints Ronald Silver interim CFO; approves $12,250 monthly fee and 25,000 RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Monthly interim assignment fee of $12,250 approved for interim CFO Silver effective May 19, 2026.","Silver received 25,000 RSUs vesting 50% each anniversary over two years.","Fee and RSUs remain until permanent CFO appointed or interim assignment ends.","Silver also serves as SVP, Corporate Controller and Chief Accounting Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50405,"accession_number":"0001104659-26-059814","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2026-05-13T12:00:30+00:00","items":["5.02"],"status":"ready","headline":"Ironwood CFO Gregory Martini resigns; Ronald Silver named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregory Martini resigns as SVP, CFO effective May 15, 2026, not due to any disagreement with the company on financial reporting.","Ronald Silver, SVP Corporate Controller and CAO, appointed interim CFO and principal financial officer effective May 15, 2026.","Silver joined Ironwood in June 2018; served as Corporate Controller and CAO since January 2025.","Silver is a CPA with prior roles at Eze Software Group and RSM, LLP, and holds a B.S. from U. Maryland and MBA from Georgetown.","No family relationships with directors/executives; no transactions requiring disclosure under Reg S-K Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92914,"accession_number":"0001104659-26-056656","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q1 2026: Revenue $107M (+159% YoY); GAAP EPS $0.25 from -$0.23; LINZESS sales $273M (+97%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $41M ($0.25 basic EPS) vs loss $37M ($0.23 loss) in Q1 2025.","LINZESS U.S. net sales $273M, up 97% YoY; 5% EUTRx demand growth.","Adjusted EBITDA $77M vs negative $4.7M a year ago.","Maintains full-year 2026 guidance; on track to start apraglutide Phase 3 trial in Q2 2026.","sNDA for LINZESS in pediatric FC (2-5yrs) accepted with priority review; PDUFA May 24."],"consensus_eps_estimate":0.2448,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":106506000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104142,"accession_number":"0001104659-26-026123","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ironwood satisfied liquidity conditions under credit agreement; maturity unchanged at Dec 31, 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company notified administrative agent that liquidity conditions in the credit agreement were satisfied.","Revolving credit facility maturity date remains December 31, 2028, per the credit agreement terms.","Credit agreement originally dated May 21, 2023, amended September 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104141,"accession_number":"0001104659-26-019405","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q4 revenue $47.7M, GAAP net loss $2.3M; FY adj EBITDA $138M, guides FY26 >$300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 total revenue $296M, GAAP net income $24M ($0.15 diluted EPS), adjusted EBITDA $138M.","Q4 2025 total revenue $47.7M (down 47% YoY); GAAP net loss $2.3M vs net income $2.3M in Q4 2024.","LINZESS EUTRx demand grew 11% YoY in FY2025; over 5.7M unique patients treated since launch.","Provides FY2026 guidance: LINZESS U.S. net sales $1.125-1.175B, total revenue $450-475M, adj EBITDA >$300M.","Apraglutide confirmatory Phase 3 trial (STARS-2) design finalized; site initiations expected Q2 2026."],"consensus_eps_estimate":0.0102,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":296151000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104140,"accession_number":"0001104659-26-000057","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood issues FY 2026 guidance; LINZESS net sales targeted at $1.125-1.175B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY 2026 LINZESS U.S. net sales guided at $1.125B-$1.175B; total revenue $450M-$475M.","FY 2026 adjusted EBITDA expected >$300M; FY 2025 guidance maintained at >$135M.","Ended Q4 2025 with >$200M cash; LINZESS list price reduced effective Jan 1, 2026.","FDA aligned on confirmatory Phase 3 trial design for apraglutide (SBS-IF); trial to start H1 2026.","Strategic alternatives review ongoing to maximize shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120412,"accession_number":"0001104659-25-123974","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ironwood subsidiary settles Ferring IP litigation with $12.5M payment, license amendment","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["VectivBio to pay Ferring $12.5M ($7.5M upfront, $5M by Dec 31, 2026) under amended license.","High single-digit royalty on net sales for 7 years after first commercial sale, then low single-digit royalty.","Amendment resolves Ferring's trade secret misappropriation lawsuit in E.D. Tex.","Ironwood guarantees VectivBio's $12.5M payment obligations under the amendment.","Clarified ownership of Contested Patents and Arising Intellectual Property exclusively to VectivBio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120411,"accession_number":"0001104659-25-116217","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HHS sets LINZESS Maximum Fair Price at $136 per 30-day supply starting Jan 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MFP for LINZESS (linaclotide) is $136 for a 30-day supply, effective January 1, 2027.","Ironwood says the MFP is in line with company expectations.","LINZESS was selected in the latest round of IRA government price setting.","MFP will become the new Medicare net price for the drug."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120410,"accession_number":"0001104659-25-108806","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q3 LINZESS sales up 40% YoY to $315M; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP net income $40M ($0.23 diluted EPS) vs $3.6M a year ago; adjusted EBITDA $82M vs $34.5M.","LINZESS US net sales $315M (+40% YoY); EUTRx demand growth +12% YoY.","Raises FY2025 LINZESS net sales guidance to $860-$890M; total revenue $290-$310M; adjusted EBITDA >$135M.","FDA approved LINZESS for IBS-C in children ages 7+; first drug for that indication.","Plans to align with FDA on apraglutide Phase 3 trial design, start confirmatory study H1 2026; strategic alternatives review ongoing."],"consensus_eps_estimate":0.102,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":248442000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120409,"accession_number":"0001104659-25-098523","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ironwood Pharmaceuticals director Andrew Dreyfus resigns effective Nov 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Dreyfus resigned from the Board, effective November 1, 2025.","Resignation due to his appointment as President and CEO of NIHCM Foundation.","No disagreement with Ironwood's operations, policies, or practices.","Company expressed gratitude for his service on the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136992,"accession_number":"0001104659-25-087008","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ironwood regains Nasdaq minimum bid price compliance after cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Aug 29, 2025 confirming compliance with Bid Price Rule.","Previously disclosed non-compliance on May 28, 2025 for failing $1.00 minimum bid.","Cured by maintaining $1.00+ closing bid for 10 consecutive business days.","Matter is now closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136991,"accession_number":"0001104659-25-074972","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Pharmaceuticals Reports Q2 2025 Results; LINZESS U.S. Net Sales $248M, GAAP Net Income $23.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LINZESS generated $248M in U.S. net sales in Q2 2025, with 10% year-over-year EUTRx demand growth.","GAAP net income was $23.6M in Q2 2025, compared to a net loss of $0.9M in Q2 2024.","Adjusted EBITDA was $50.1M in Q2 2025, up from $36.5M in Q2 2024.","Company plans to align with FDA on confirmatory Phase 3 trial design for apraglutide in Q4 2025.","Ironwood is actively progressing a strategic alternatives review to maximize shareholder value."],"consensus_eps_estimate":0.0408,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":126382000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136990,"accession_number":"0001104659-25-066986","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ironwood dismisses EY as auditor; appoints KPMG; prior adverse ICFR opinion cited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Ernst & Young as independent auditor on July 3, 2025; no disagreements during fiscal 2023 and 2024.","EY's report on internal controls for fiscal 2024 contained adverse opinion due to material weaknesses in entity-level and ITGC controls.","Material weaknesses also impacted financial close process and expenditure controls; no restatement required.","Audit Committee appointed KPMG as new independent auditor effective immediately for FY 2025.","EY agreed with disclosures; furnished letter to SEC dated July 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154267,"accession_number":"0001104659-25-058883","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ironwood stockholders elect nine directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; Jay Shepard received 111,094,136 votes for, highest tally.","Non-binding advisory vote on executive compensation passed with 110,089,576 for vs. 3,511,070 against.","Ratification of Ernst & Young as independent auditor for 2025 passed with 128,241,210 for vs. 2,621,956 against.","Broker non-votes totaled 17,527,704 on director election and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154266,"accession_number":"0001104659-25-055958","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ironwood receives Nasdaq deficiency notice for bid price below $1.00; has until Nov 24, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received deficiency letter on May 28, 2025 for bid price below $1.00 for 30 consecutive business days.","Compliance period of 180 calendar days, until November 24, 2025, to regain minimum bid price.","To cure, bid price must close at $1.00 or more for at least 10 consecutive business days.","If not compliant by deadline, company may qualify for additional 180 days by moving to Nasdaq Capital Market.","No immediate effect on listing; company monitoring options but cannot assure compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154265,"accession_number":"0001104659-25-045310","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q1 net loss $37.4M; revenue down 45% YoY; raises adjusted EBITDA guidance to >$105M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue of $41.1M vs $74.9M in Q1 2024, down 45% YoY.","GAAP net loss $37.4M ($0.23 loss per share) vs $4.2M loss a year ago.","Adjusted EBITDA guidance raised to >$105M for FY 2025; on track to meet full-year guidance.","LINZESS prescription demand grew 8% YoY in Q1 2025, in line with expectations.","Company is exploring strategic alternatives to maximize stockholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":41143000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154264,"accession_number":"0001104659-25-039013","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood reiterates FY2025 LINZESS guidance, raises EBITDA to >$105M; Q1 net sales down 46%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reiterates FY2025 LINZESS U.S. net sales guidance of $800-$850M and total revenue of $260-$290M.","Raises FY2025 adjusted EBITDA guidance to >$105M (from >$85M).","Q1 2025 LINZESS U.S. net sales were $138.5M, a 46% decrease YoY due to change in AbbVie's gross-to-net rebate estimate.","Q1 2025 LINZESS prescription demand grew 8% YoY to 53M capsules, per IQVIA.","Shifts apraglutide focus to confirmatory Phase 3 trial after FDA feedback; no longer plans certain commercial launch investments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":41143000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154263,"accession_number":"0001104659-25-034381","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA requires confirmatory Phase 3 trial for apraglutide; Ironwood explores strategic alternatives","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA feedback indicates a confirmatory Phase 3 trial is needed to seek approval of apraglutide for SBS-IF; company will work on design and regulatory path.","Pharmacokinetic analysis found exposure and dose in STARS Phase 3 trial were lower than planned due to dose preparation and administration.","Ironwood has engaged Goldman Sachs & Co. LLC to explore strategic alternatives to maximize stockholder value.","Long-term extension data: 27 apraglutide-dosed patients achieved enteral autonomy (no parenteral support); STARS data remains part of NDA package."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172854,"accession_number":"0001104659-25-028766","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Ironwood receives Nasdaq notice for late 10-K filing; 60 days to submit compliance plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Ironwood on March 21, 2025 of non-compliance due to delayed 2024 Form 10-K filing.","Company has until May 20, 2025 to submit a plan; if accepted, extension to September 1, 2025.","No immediate effect on listing; Ironwood expects to file 2024 Form 10-K as soon as practicable.","Press release issued March 27, 2025; standard Nasdaq procedure for late filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172853,"accession_number":"0001104659-25-017774","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood FY2024 revenue $351M, net income positive; apraglutide NDA rolling initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $90.5M in Q4 and $351.4M for FY2024, down 23% YoY from $442.7M in FY2023.","GAAP net income $1.8M in FY2024 vs. loss of $1.0B in FY2023 (prior year included impairment).","Adjusted EBITDA $100.6M for FY2024, a significant improvement from $(884.8)M in FY2023.","LINZESS prescription demand grew 11% YoY in FY2024; company achieved 2024 financial guidance.","Rolling NDA submission for apraglutide (SBS) initiated, on track for completion in Q3 2025; OLE data showed 27 patients achieving enteral autonomy."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":351410000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172852,"accession_number":"0001104659-25-007212","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"Ironwood cuts workforce ~50%, promotes Gregory Martini to CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~50% approved Jan 17, targeting primarily field-based sales employees; affected employees notified Jan 29.","Expects to incur $20M-$25M in charges, mostly severance and benefits, substantially in H1 2025; post-reduction headcount ~120.","Gregory Martini promoted to SVP, CFO effective Jan 27; succeeds Thomas McCourt who remains CEO.","Martini receives base salary $485k, bonus target 45%, and 111,111 RSUs vesting over 4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189862,"accession_number":"0001104659-24-125937","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ironwood CFO Sravan Emany resigns effective Dec 18; CEO McCourt interim PFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sravan Emany resigns as SVP, COO, and CFO effective Dec 18, 2024.","Resignation not due to any disagreement on financial reporting matters.","CEO Thomas McCourt will serve as interim principal financial officer.","Company will search for a new CFO; interim arrangement in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189861,"accession_number":"0001104659-24-116764","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ironwood CBO Andrew Davis resigns effective Nov 22, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Davis resigns as Senior Vice President, Chief Business Officer.","Resignation effective November 22, 2024; no replacement announced.","Davis notified company on November 6, 2024; reason not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189860,"accession_number":"0001104659-24-115052","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q3 revenue down 19% YoY to $91.6M; LINZESS Rx demand +13%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $3.6M ($0.02 diluted EPS) vs $15.3M ($0.10) a year ago.","Total revenue $91.6M, down from $113.7M in Q3 2023; cites pricing headwinds.","LINZESS new-to-brand and extended-unit prescriptions each grew 13% YoY.","Apraglutide NDA submission for short bowel syndrome on track for Q1 2025.","Full-year 2024 financial guidance reaffirmed; Adjusted EBITDA $26.2M vs $49.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":260865000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206378,"accession_number":"0001104659-24-103925","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Ironwood amends credit facility to $550M, extends maturity to 2028; declines CNP-104 option","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility increased from $500M to $550M; $400M outstanding as of amendment date.","Maturity extended to earlier of Dec 31, 2028 or 91 days before convertible notes maturity, subject to liquidity.","Maximum consolidated secured net leverage ratio raised to 3.50x (initial period), stepping down to 3.00x; can rise further for acquisitions over $50M.","Ironwood will not exercise option for CNP-104 (primary biliary cholangitis); collaboration with COUR terminates, no further rights or obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206377,"accession_number":"0001104659-24-086992","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q2 revenue down 12% to $94.4M; cuts FY 2024 guidance on Medicaid pricing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $94.4M in Q2 2024, down 12% from $107.4M in Q2 2023; FY 2024 guidance revised lower due to pricing pressure.","LINZESS prescription demand up 11% YoY but Medicaid utilization drove pricing headwinds; new-to-brand growth 15%.","GAAP net loss of $0.9M (($0.01)/share) vs $1.06B loss in Q2 2023; adjusted EBITDA of $27.9M vs $(1.03B) last year.","Plans to pursue apraglutide rolling NDA for short bowel syndrome; expects submission in Q1 2025. CNP-104 topline results on track for Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":169273000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223486,"accession_number":"0001104659-24-073736","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ironwood shareholders elect nine directors, approve executive pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with over 130 million votes each for a one-year term.","Advisory vote on executive compensation passed with ~127.4 million for, ~8.0 million against.","Ratification of Ernst & Young as auditor for 2024 approved with ~136.8 million for, ~6.3 million against.","Meeting held June 18, 2024; all proposals received majority support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223485,"accession_number":"0001104659-24-073391","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Ironwood repays $200M convertible notes at maturity using cash and revolver; CFO adds COO role","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $200M 0.75% Convertible Senior Notes due 2024 on June 17 using $50M cash and $150M from $500M revolver.","Outstanding balance on $500M revolver increased to $425M following the $150M draw.","Expects ~$100M cash and cash equivalents as of June 30, 2024 (preliminary estimate).","Sravan K. Emany, current CFO, also appointed Chief Operating Officer effective immediately.","Emany has been CFO since Dec 2021; no family relationships or transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223484,"accession_number":"0001104659-24-059101","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q1 revenue down 28% YoY, net loss $4.2M; apraglutide Phase III positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $74.9M vs $104.1M YoY; GAAP net loss of $4.2M vs net income of $45.7M.","LINZESS prescription demand grew 10% YoY; revenue impacted by gross-to-net change.","Positive Phase III STARS trial of apraglutide in SBS-IF; NDA filing planned.","Revised FY 2024 guidance due to LINZESS gross-to-net change estimate.","Adjusted EBITDA fell to $12.8M from $60.4M YoY; non-GAAP net loss per share $(0.02)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":74877000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242937,"accession_number":"0001104659-24-024345","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood reports FY2023 GAAP net loss of $1.0B; LINZESS sales $1.1B (+7%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 total revenue $442.7M; LINZESS collaboration revenue $430M; Q4 revenue $117.6M.","FY2023 GAAP net loss attributable to Ironwood $1.002B ($6.45 diluted loss/share), vs FY2022 net income $175M.","LINZESS U.S. net sales $1.1B (+7% YoY), prescription demand +10% YoY; pediatric IBS-C approval in June 2023.","Expects topline STARS Phase 3 study of apraglutide in SBS-IF in March 2024; CNP-104 Phase 2 data in Q3 2024.","FY2023 adjusted EBITDA loss $884.8M (includes impairment), vs positive $251.8M in FY2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":442735000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242936,"accession_number":"0001104659-24-001989","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood guides FY2024 adj EBITDA >$150M, LINZESS low-single digit growth, pipeline catalysts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maintains FY2023 guidance: LINZESS net sales growth 6-8%, revenue $435-450M, adjusted EBITDA ~($900M) from VectivBio charge.","FY2024 guidance: LINZESS U.S. net sales low-single digit % growth, total revenue $435-455M, adjusted EBITDA >$150M.","Expects apraglutide STARS Phase 3 topline data in SBS-IF in March 2024; CNP-104 Phase 2 topline data in PBC in Q3 2024.","High-single digit LINZESS prescription demand growth in 2024 offset by mid-to-high single digit price erosion from Medicaid AMP cap removal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260303,"accession_number":"0001104659-23-115985","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q3 total revenue $113.7M, GAAP diluted EPS $0.09 vs $0.28 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $113.7M (up 5% YoY); GAAP net income $15.3M, diluted EPS $0.09 vs $0.28.","LINZESS U.S. net sales $279M (+7% YoY); prescription demand +8%.","Positive final data from Phase II STARS Nutrition study of apraglutide in SBS-IF with CIC.","Expects topline data for CNP-104 in primary biliary cholangitis in Q3 2024.","Maintains full year 2023 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":325182000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277595,"accession_number":"0001104659-23-099708","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K/A","filed_at":"2023-09-11T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Ironwood files audited VectivBio financials: 2022 net loss $94M, 2021 & 2022 restated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VectivBio 2022 revenue $27.3M from Asahi Kasei partner deal; net loss $94.1M.","VectivBio held $221.4M cash at Dec 31, 2022; total assets $252.6M.","Restated 2021 and 2022 statements to correct a misstatement; no further details here.","Pro forma combined results for Ironwood + VectivBio for H1 2023 and FY2022 included in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277596,"accession_number":"0001104659-23-088584","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood posts Q2 GAAP net loss of $1.06B on acquisition costs; LINZESS sales +9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss attributable to Ironwood of $1.06B, or $6.84/share diluted, primarily from VectivBio acquisition.","Total revenues $107.4M, up 10% YoY; LINZESS U.S. net sales $270M, +9% YoY.","FDA approved LINZESS for pediatric FC ages 6-17 in June, expanding addressable market.","Acquired VectivBio for apraglutide (SBS-IF); STARS Phase III enrollment complete, data March 2024.","Raised full-year 2023 guidance: LINZESS net sales $1.055-1.075B, Ironwood revenue $435-455M."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":211443000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295574,"accession_number":"0001104659-23-077076","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["2.01","2.03","8.01","9.01"],"status":"ready","headline":"Ironwood completes $1.15B tender offer for VectivBio, acquires ~97.6% of shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tendered 59.3M shares represent ~94.4% plus 2.0M via guaranteed delivery (~97.6% total).","Offer price $17/share cash; total consideration ~$1.15B.","Borrowed $400M under Revolving Credit Agreement to fund portion.","Plans to delist VectivBio shares from Nasdaq and execute Swiss squeeze-out merger.","Ironwood appointed new directors to VectivBio board effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295573,"accession_number":"0001104659-23-073747","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Ironwood shareholders approve new equity plan and director slate at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected, including Mark Currie, Alexander Denner, Andrew Dreyfus, Jon Duane, Marla Kessler, Thomas McCourt, Julie McHugh, Catherine Moukheibir, Jay Shepard.","Non-binding advisory vote on executive compensation approved: 124,448,271 for, 2,240,534 against, 261,827 abstain.","Stockholders recommended future say-on-pay votes every year (121,938,287 for 1-year; broker non-votes 8,009,329).","Amended and Restated 2019 Equity Incentive Plan approved: 119,042,503 for, 7,783,479 against; adds up to 16,000,000 new shares plus prior plan forfeitures.","Ratification of Ernst & Young as auditor for 2023: 131,145,295 for, 3,631,560 against, 183,106 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295572,"accession_number":"0001104659-23-063162","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Ironwood to acquire VectivBio for $17.00/share; secures $500M credit facility","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash tender offer at $17.00/share for all VectivBio shares; minimum tender condition >80%.","Termination fees: VectivBio pays $23.68M if superior proposal; Ironwood pays $59.2M reverse fee.","$500M revolving credit facility from Wells Fargo; matures 2027; secured by substantially all assets.","Support agreement with shareholders owning ~28.6% of VectivBio shares agreeing to tender and vote.","VectivBio shareholders must remove voting cap and elect Ironwood designees to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295571,"accession_number":"0001104659-23-055770","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q1 2023: net income $45.7M ($0.30 EPS); LINZESS demand up 10% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $104.1M, up 7% YoY; GAAP net income $45.7M vs $38.8M.","LINZESS U.S. net sales $250M (+8% YoY); prescription demand grew 10% YoY.","Ended Q1 with $740M cash; full-year 2023 financial guidance maintained.","PDUFA date June 14 for potential pediatric functional constipation indication in ages 6-17."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":104061000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295570,"accession_number":"0001104659-23-043844","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2023-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ironwood eliminates COO role; Jason Rickard to depart May 12, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Company eliminated COO role to streamline executive leadership team.","Jason Rickard's last day as SVP, COO and employee is May 12, 2023.","COO responsibilities distributed to other leadership team members, with Rickard's support for transition.","Rickard eligible for severance under existing agreement; role elimination not due to disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316107,"accession_number":"0001104659-23-022597","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood reports FY 2022 GAAP net income $175M; FDA grants priority review for LINZESS pediatric sNDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2022 total revenues $410.6M (down ~1% YoY); GAAP net income $175.1M vs $528.4M in FY 2021.","Q4 2022 total revenues $107.2M; GAAP net income $48.9M ($0.27 diluted EPS).","Adjusted EBITDA for FY 2022 was $252M, up from $234M in FY 2021; cash and equivalents $656M.","FDA granted priority review for LINZESS sNDA for pediatric functional constipation (ages 6-17); PDUFA date Q2 2023.","CEO cited robust prescription demand but lower LINZESS sales growth due to retail channel inventory fluctuations."],"consensus_eps_estimate":null,"consensus_eps_actual":0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":410596000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316106,"accession_number":"0001104659-23-002024","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood cuts FY2022 revenue guidance to ~$411M; issues FY2023 outlook and files sNDA for pediatric LINZESS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Updated FY2022: total revenue ~$411M (prev. $420-430M), LINZESS net sales ~0% growth, adj. EBITDA ~$250M.","FY2023 guidance: revenue $420-435M, LINZESS net sales growth 3-5%, adj. EBITDA >$250M.","sNDA submitted to FDA for LINZESS in functional constipation in children 6-17; if approved, first FDA therapy for this population.","Expects ~$650M cash at YE2022; high single-digit LINZESS prescription demand growth in 2023.","Clinical milestone: CNP-104 data expected in H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":410596000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334421,"accession_number":"0001104659-22-114196","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q3 GAAP net income $50M; LINZESS Rx demand up 10% YoY, surpasses 1M quarterly scripts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income of $50M ($0.28 diluted EPS); adjusted EBITDA $69M; total revenue $108.6M vs. $103.7M YoY.","LINZESS prescription demand grew 10% YoY in Q3; exceeded 1M total prescriptions in a quarter for first time.","Plan to submit sNDA to FDA for functional constipation in pediatric patients (ages 6-17) by end of 2022.","Reaffirms FY2022 guidance: total revenue $420-$430M, adjusted EBITDA >$250M, LINZESS net sales low single digit % growth.","Ended Q3 with $574M cash; no debt on balance sheet; strong liquidity position."],"consensus_eps_estimate":null,"consensus_eps_actual":0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":303397000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351841,"accession_number":"0001104659-22-085865","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q2 2022 GAAP net income $37M; LINZESS Rx demand up 9% YoY; guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income of $37M ($0.21 diluted EPS); adjusted EBITDA of $56M; total revenue $97.2M, down 7% YoY.","LINZESS EUTRx prescription demand grew 9% year-over-year in Q2 2022.","Completed $75M share repurchase program and repaid remaining 2022 Convertible Notes in cash.","Reiterated 2022 guidance: low single-digit % LINZESS net sales growth, total revenue $420-$430M, adjusted EBITDA >$250M.","Phase 3 pediatric linaclotide study for functional constipation expected to readout in Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":194760000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369272,"accession_number":"0001104659-22-068072","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ironwood shareholders elect 9 directors, approve say-on-pay, ratify E&Y at 2022 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nine director nominees elected with votes for ranging from ~110.1M to ~124.3M; Alexander Denner received most withheld (~15.9M).","Say-on-pay advisory vote passed: ~122.3M for, ~3.4M against, ~393,566 abstain.","Ratification of Ernst & Young as independent auditor for 2022 approved: ~131.9M for, ~2.7M against, ~109,800 abstain.","Broker non-votes of 8,607,404 on first two items and none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369271,"accession_number":"0001104659-22-056130","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q1 2022: LINZESS Rx demand +11%; net sales $232M; GAAP net income $39M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LINZESS U.S. net sales $232M (+8% YoY); prescription demand growth +11% YoY.","Total revenue $98M; GAAP net income $39M ($0.21 diluted EPS).","Adjusted EBITDA $58M, up from $46M; cash and equivalents $593M.","Full-year 2022 financial guidance reaffirmed; LINZESS exceeded $1B in 2021.","CEO cites progress in clinical trials and plans to in-license or acquire GI assets."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":97529000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388470,"accession_number":"0001104659-22-024468","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood Q4/FY2021: LINZESS blockbuster >$1B; total revenue $414M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 total revenue $414M (driven by $400M LINZESS collab revenue); GAAP net income $528M (incl $338M tax benefit).","Adjusted EBITDA $234M; year-end cash $620M.","Non-GAAP diluted EPS $1.16 vs $0.79 in FY2020; Q4 Non-GAAP EPS $0.27.","Initiated clinical studies for IW-3300 (visceral pain) and CNP-104 (primary biliary cholangitis).","LINZESS U.S. net sales exceeded $1B in 2021, achieving blockbuster status."],"consensus_eps_estimate":null,"consensus_eps_actual":3.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":413753000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388469,"accession_number":"0001104659-22-002490","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ironwood expects LINZESS to exceed $1B in 2021 US net sales; raises 2021 adjusted EBITDA guidance to >$230M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LINZESS U.S. net sales expected to surpass $1B in 2021, achieving blockbuster status.","2021 guidance updated: LINZESS growth at high end of 6-8%; total revenue high end of $390-410M.","Adjusted EBITDA guidance raised to >$230M (from >$210M) for 2021.","2022 guidance: LINZESS low single-digit growth; total revenue $420-430M; adjusted EBITDA >$250M.","Board authorized $150M share repurchase; $27M repurchased in Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":3.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":413753000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406397,"accession_number":"0001104659-21-145194","cik":1446847,"company_name":"IRONWOOD PHARMACEUTICALS INC","ticker":"IRWD","form_type":"8-K","filed_at":"2021-12-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ironwood appoints Sravan Emany as CFO, effective Dec 6, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sravan K. Emany named SVP, CFO effective Dec 6, 2021; Jason Rickard remains COO.","Emany previously corporate VP at Integra LifeSciences and managing director at BofA.","Base salary $500k, bonus target 50% of base, $200k sign-on bonus, 85k RSUs and 85k PSUs.","Emany to enter indemnification and executive severance agreement (filed as Exhibit 10.1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":606287632.4022372,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-12-01T23:59:59+00:00|406397"}